Lido Advisors
JAZZ icon

Lido Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Lido Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,200
Closed -$551K – 459
2018
Q2 		$551K Buy
+3,200
New +$523K 0.06% 184
2018
Q1 		– Sell
-3,200
Closed -$430K – 415
2017
Q4 		$430K Buy
+3,200
New +$444K 0.06% 174

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Lido Advisors's JAZZ Position: Q2 2026 in Review

Lido Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 100% in Q2 2026, buying an estimated $276K and bringing the position to 2,513 shares worth $606K. The position accounts for ﹤0.01% of the portfolio, ranked #1363.

Lido Advisors first reported a position in JAZZ in Q3 2017 and has held it in 7 quarters since. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Lido Advisors held 2,513 shares of Jazz Pharmaceuticals worth $606K as of Q2 2026.
  • Lido Advisors bought 1,259 Jazz Pharmaceuticals shares in Q2 2026, an estimated $276K.
  • Jazz Pharmaceuticals made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #1363 holding.
  • Lido Advisors first reported a position in Jazz Pharmaceuticals in Q3 2017 and has held it in 7 quarters since.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.